CoChat

l -Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Objective The authors conducted two multicenter sequential parallel comparison design trials to investigate the effect of L-methylfolate augmentation in the treatment of major depressive disorder in patients who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs). Method In the first trial, 148 outpatients with SSRI-resistant major depressive disorder were enrolled in a 60-day study divided into two 30-day periods. Patients were randomly assigned, in a 2:3:3 ratio, to receive L-methylfolate for 60 days (7.5 mg/day for 30 days followed by 15 mg/day for 30 days), placebo for 30 days followed by L-methylfolate (7.5 mg/day) for 30 days, or placebo for 60 days. SSRI dosages were kept constant throughout the study. In the second trial, with 75 patients, the design was identical to the first, except that the l-methylfolate dosage was 15 mg/day during both 30-day periods. Results In the first trial, no significant difference was observed in outcomes between the treatment groups. In the second trial, adjunctive L-methylfolate at 15 mg/day showed significantly greater efficacy compared with continued SSRI therapy plus placebo on both primary outcome measures (response rate and degree of change in depression symptom score) and two secondary outcome measures of symptom severity. The number needed to treat for response was approximately six in favor of adjunctive L-methylfolate at 15 mg/day. L-Methylfolate was well tolerated, with rates of adverse even…

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2012.11071114

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 3

  1. 10.3109/10401230209147396 · doi:10.3109/10401230209147396 · Paper page
  2. Passeri M, 1993, Aging (Milano), 5, 63
  3. First MB, 1995, Structured Clinical Interview for DSM-IV Axis I Disorders With Psychotic Screen (SCID-I/P w/ Psychotic Screen) Version 2.0

Cited by

See all 285

Metadata

Authors
Papakostas, G. I., Shelton, R. C., Zajecka, J. M., Etemad, B., Rickels, K., Clain, A., Baer, L., Dalton, E. D., Sacco, G. R., Schoenfeld, D., Pencina, M., Meisner, A., Bottiglieri, T., Nelson, E., Mischoulon, D., Alpert, J. E., Barbee, J. G., Zisook, S., & Fava, M.
Affiliations
  • Boston University (US)
  • From the Center for Treatment-Resistant Depression, Depression Clinical and Research Program, the Biostatistics Center, and the Clinical Trials Network and Institute, Massachusetts General Hospital, Boston; Harvard Medical School, Boston; the Harvard Clinical Research Institute, Boston; the Department of Biostatistics, Boston University, Boston; the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville; Rush University Medical Center, Chicago; the Department of Psychiatry,...
Venue
American Journal of Psychiatry
Published
2012-12
Volume
169
Issue
12
Pages
1267-1274
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2136722242
Cited by
275
References
36
Citations by year
2026: 21 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 20 · 2020: 18 · 2019: 22 · 2018: 27 · 2017: 19 · 2016: 26 · 2015: 26 · 2014: 25 · 2013: 25 · 2012: 1
FWCI
18.11
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
5-methyltetrahydrofolate, major depressive disorder, selective serotonin reuptake inhibitors, adjunctive therapy, treatment-resistant depression, antidepressant augmentation, response rate, adverse events, folic acid supplementation
MeSH terms
Major Depressive Disorder, Depressive Disorder, Major, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Tetrahydrofolates, Treatment Outcome, Chemotherapy, Adjuvant, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.